{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-009168","form_type":"8-K","ticker":"RFAI","cik":"0002012807","company_name":"RF Acquisition Corp II","filed_at":"2026-08-20T20:49:43+00:00","discovered_at":"2026-08-20T20:51:01.369701+00:00","generated_at":"2026-08-20T20:51:10.349229+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RF Acquisition Corp II shareholders approve Nanyang Biologics deal; 3.96M shares seek redemption","bullets":["All six proposals approved at Aug 19 EGM: 6,765,584 for, 440,604 against, 0 abstain.","Preliminary redemption requests for 3,956,323 ordinary shares from trust account (~47.4% of outstanding).","Business combination with Nanyang Biologics Pte. Ltd. via NYB Holdings remains subject to closing conditions.","Quorum of 7,206,188 shares (86.36%) present; record date May 20, 2026.","Redemption requests may be withdrawn with consent; final per-share price and trust proceeds pending closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-009168","json":"https://secwatch.observer/filing/0001829126-26-009168.json","markdown":"https://secwatch.observer/filing/0001829126-26-009168.md","text":"https://secwatch.observer/filing/0001829126-26-009168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012807/000182912626009168/0001829126-26-009168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012807/000182912626009168/rfacquisition2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-20T20:51:10.349229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}